Sepsia Therapeutics
Pioneering innovative broad-spectrum drug and cellular therapies to combat sepsis by targeting infection-induced inflammatory responses.
Pioneering innovative broad-spectrum drug and cellular therapies to combat sepsis by targeting infection-induced inflammatory responses.
Founded in 1996, Sepsia Therapeutics is a biotechnology and pharmaceutical company that is pioneering innovative broad-spectrum drug and cellular therapies to combat sepsis. Their focus lies in targeting infection-induced inflammatory responses, a dangerous condition triggered by the body's response to infections, primarily bacterial and fungal.
The company's approaches utilize scavenger-like receptors on the surfaces of lymphocyte cells. These receptors are leveraged to bind and neutralize the conserved inflammation-promoting structures of harmful microbes. Furthermore, these structures provide new therapeutic targets that address both microbial virulence factors and the body's inflammatory and immune responses.
As of 01 January 2019, the company secured a notable €71.43K grant investment from the EASME - EU Executive Agency for SMEs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | €71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Jan 2019 |
No recent news or press coverage available for Sepsia Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
